ICU Medical, Inc. (NASDAQ:ICUI) Position Raised by Woodline Partners LP

Woodline Partners LP raised its stake in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 122,239 shares of the medical instruments supplier's stock after buying an additional 5,300 shares during the period. Woodline Partners LP owned approximately 0.50% of ICU Medical worth $18,968,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of ICUI. Norges Bank bought a new position in shares of ICU Medical in the fourth quarter valued at $40,151,000. Point72 Asset Management L.P. increased its holdings in shares of ICU Medical by 63.2% in the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock valued at $38,069,000 after buying an additional 95,030 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of ICU Medical by 18.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 539,981 shares of the medical instruments supplier's stock valued at $83,788,000 after buying an additional 82,982 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of ICU Medical in the fourth quarter valued at $10,003,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of ICU Medical by 7.4% in the fourth quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier's stock valued at $109,920,000 after buying an additional 49,108 shares in the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $130.75 on Thursday. The company's fifty day moving average is $140.42 and its two-hundred day moving average is $153.32. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a 12-month low of $100.91 and a 12-month high of $196.26. The company has a market cap of $3.22 billion, a P/E ratio of -28.61 and a beta of 0.87.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. The company had revenue of $599.49 million for the quarter, compared to the consensus estimate of $574.15 million. During the same period in the previous year, the business earned $0.96 EPS. The company's revenue was up 6.7% on a year-over-year basis. Equities analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Christian B. Voigtlander sold 5,555 shares of the business's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $138.00, for a total transaction of $766,590.00. Following the transaction, the chief operating officer now directly owns 2,389 shares in the company, valued at $329,682. The trade was a 69.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David C. Greenberg sold 1,942 shares of the business's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total transaction of $278,987.72. Following the transaction, the director now owns 6,760 shares in the company, valued at approximately $971,141.60. This represents a 22.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,208 shares of company stock worth $2,926,969 in the last ninety days. Corporate insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on ICUI. KeyCorp dropped their price target on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Raymond James dropped their price target on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday, May 9th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research note on Tuesday, April 8th. Finally, StockNews.com raised shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Sunday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ICU Medical presently has a consensus rating of "Buy" and an average target price of $192.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.